Viewing data from:

GEMMILY

ANDA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE | A213317 | XIROMED PHARMA ESPANA SL

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: TAYTULLA(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$0.6605

per ea

Lowest NADAC/Unit

$0.6605

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
70700015285GEMMILY 1 MG-20 MCG CAPSULE	$0.6605	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

Medicare Part D Spending

CMS annual spending data for Gemmily (2024)

Total Spending

$9K

Total Claims

Beneficiaries

Avg Cost/Unit

$2.28

Spending Trend

$15K(2021)→$19K(2022)→$12K(2023)→$9K(2024)

YoY Change:-26.6%

5yr CAGR:-19.3%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jan 7, 2021	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 0.02MG;1MG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Nov 9, 2020

No patent or exclusivity listings for this strength.